The University of Sydney, Sydney Medical School, Sydney, NSW, Australia.
Institute of Academic Surgery at RPA Hospital, Sydney, NSW, Australia.
Ann Surg Oncol. 2021 Jun;28(6):3092-3099. doi: 10.1245/s10434-020-09431-4. Epub 2021 Jan 2.
The vermilion lip is a unique anatomical junction between cutaneous and mucosal surfaces. Squamous cell carcinoma (SCC) of the vermilion lip (vlSCC) was previously classified as oral SCC (oSCC) under the American Joint Committee on Cancer (AJCC) 7th edition (AJCC7), but has been recategorized as a cutaneous SCC of the head and neck (HNcSCC) in the AJCC 8th edition (AJCC8). We investigated the locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) for the various pathological T categories and disease stages of vlSCC as per AJCC8.
We performed a retrospective cohort study of 297 patients diagnosed with vlSCC between January 2004 and February 2019. For this study, vlSCC cases were staged according to both AJCC7 and AJCC8. Kaplan-Meier survival curves and Cox regression models were used to analyze differences in LRC, DFS, and OS between each pT category and disease stage, and log-rank tests were performed for subgroup analysis.
Restaging of vlSCC using the AJCC8 resulted in 19% of patients being upstaged to pT3, and 16% being upstaged to stage III. No patients were downstaged in pT stage or overall stage.
Our study shows that when the AJCC8 HNcSCC staging system is applied to vlSCC, there are important aberrations leading to unwarranted upstaging of pT1 and redundancy of pT2. Understanding of these limitations are important in considering treatment escalation.
红唇是皮肤和黏膜表面之间独特的解剖交界。唇红鳞状细胞癌(vlSCC)以前根据美国癌症联合委员会(AJCC)第 7 版(AJCC7)被归类为口腔鳞状细胞癌(oSCC),但在 AJCC 第 8 版(AJCC8)中已重新归类为头颈部皮肤鳞状细胞癌(HNcSCC)。我们根据 AJCC8 研究了各种病理 T 分期和疾病阶段的 vlSCC 的局部区域控制(LRC)、无病生存(DFS)和总生存(OS)。
我们对 2004 年 1 月至 2019 年 2 月期间诊断为 vlSCC 的 297 例患者进行了回顾性队列研究。为了进行这项研究,vlSCC 病例根据 AJCC7 和 AJCC8 进行分期。Kaplan-Meier 生存曲线和 Cox 回归模型用于分析每个 pT 分期和疾病阶段之间的 LRC、DFS 和 OS 差异,并进行对数秩检验进行亚组分析。
使用 AJCC8 对 vlSCC 进行重新分期导致 19%的患者被升级为 pT3,16%的患者被升级为 III 期。在 pT 分期或总分期中没有降级的患者。
我们的研究表明,当 AJCC8 HNcSCC 分期系统应用于 vlSCC 时,存在导致 pT1 不必要升级和 pT2 冗余的重要偏差。了解这些局限性对于考虑治疗升级很重要。